Failure Brings Atea and Roche’s COVID-19 Pill Moonshot Down To Earth

Falls Behind Merck’s Rival

 
• By Andrew McConaghie

An attempt to show efficacy even in younger people with mild COVID-19 symptoms has fallen flat in Phase II, and AT-527 will now lag behind rivals Merck and Pfizer.

Atea Pharmaceuticals
Atea's antiviral could still help COVID-19 patients, but its pivotal trial results have been set back to the second half of 2022. • Source: Alamy

More from Business

More from Scrip